Role of Ketogenic Diets and Intermittent Fasting in Neurologic Diseases, Cancers, and Obesity: A Systematic Review of Human Studies

Nikhila Chelikam, Sai Anusha Akella, Manisha Rakesh Lakhanpal, Simmy Lahori, Aryak Singh, Sana Zafar, Prashanth Gumpu Shivashankar, Lokesh Manjani, Ruslan Ilyassov, Abdirazak Ibrahim Ali, Roghayeh Marandi, Rahul Gujarathi, Divesh Manjani, Avinash Adiga, Urvish Patel

Abstract


Ketogenic diet (KD) and intermittent fasting (IF) are non-pharmacologic nutritional therapies with modest side effects such gastrointestinal discomfort, dyslipidemia, and hypomagnesemia for various medical conditions. KD and IF may help with weight loss, diabetes, cardiovascular disease, polycystic ovarian syndrome, cancer, and chronic neurological illnesses. We studied KD and IFs impact on cancer, obesity, and neurodegenerative illnesses. We advised evidence-based KD and IF safety. KD is hard to maintain despite benefits. Thus, occasional KD adoption may help newly diagnosed overweight or obese type 2 diabetics lose weight and control blood glucose and lipids. KD is a high-fat, low-carbohydrate diet with 4:1 or 3:1 fat to carbohydrates and protein, thus peripheral tissues and the brain need fatty acids for energy. Most fasting energy comes from ketones. KD has been reliably used to treat refractory epilepsy since the 1920s. KD prevents epilepsy, stroke, severe brain injury, Alzheimers, and other neurological illnesses. KD has been used to treat obesity since the 1960s. Combining chemotherapy and radiation with KD may increase tumor cell sensitivity. Thus, KD can be used to treat obesity, cancer, and chronic neurological disease without medicine or side effects. As an adjuvant therapy, KD may offer new neuroprotection and neuroscience treatments. Antioxidant defense and inflammation reduction may alleviate Alzheimers and Parkinsons risk. By targeting cancer cell metabolism, KD and IF may be used to treat cancer. Radiation and chemotherapy may be intensified when used in conjunction with KD. In aggressive brain cancer glioblastoma, KD is most promising. Ketosis suppresses hunger, aiding weight loss in overweight or obese patients. Among type 2 diabetes patients, it helps to manage blood glucose and cholesterol, but long-term adherence is difficult. If paired with exercise, IF may be more effective than calorie restriction for weight loss. Further prospective human trials are needed to assess KD and IFs therapeutic efficacy and safety.




J Endocrinol Metab. 2024;14(3):103-127
doi: https://doi.org/10.14740/jem944

Keywords


Ketogenic diet; Intermittent fasting; Neurological disorders; Traumatic brain injury; Alzheimer's disease; Behavioral disease; Cancer; Obesity

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.


Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.